<DOC>
	<DOCNO>NCT01057810</DOCNO>
	<brief_summary>The purpose study determine asymptomatic minimally symptomatic patient metastatic prostate cancer receive chemotherapy live longer treat ipilimumab treat placebo</brief_summary>
	<brief_title>Phase 3 Study Immunotherapy Treat Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Metastatic prostate cancer Asymptomatic minimally symptomatic Progression hormonal therapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Liver , lung brain metastasis Prior immunotherapy chemotherapy metastatic prostate cancer Autoimmune disease HIV , Hepatitis B , Hepatitis C infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>